Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD).

Diabetol Metab Syndr · 2025 · PMC11702049 · PMID 39757198

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In our study, it is noteworthy that after 64 weeks of treatment, the improvement in the rate of change in eGFR was borderline significant.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.